Compare · LXRX vs NVS
LXRX vs NVS
Side-by-side comparison of Lexicon Pharmaceuticals Inc. (LXRX) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LXRX and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $279.39B, about 334.6x LXRX ($835.1M).
- Over the past year, LXRX is up 154.3% and NVS is up 26.3% - LXRX leads by 128.0 points.
- LXRX has hit the wire 9 times in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 5 for LXRX).
- Company
- Lexicon Pharmaceuticals Inc.
- Novartis AG
- Price
- $1.88-0.79%
- $149.10+1.77%
- Market cap
- $835.1M
- $279.39B
- 1M return
- -6.25%
- +2.12%
- 1Y return
- +154.34%
- +26.32%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 9
- 0
- Recent ratings
- 5
- 25
Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest LXRX
- Director Swain Judith L converted options into 89,312 shares, increasing direct ownership by 105% to 174,486 units (SEC Form 4)
- Director Sullivan Diane E. converted options into 89,312 shares, increasing direct ownership by 243% to 126,122 units (SEC Form 4)
- Director Sobecki Christopher J converted options into 89,312 shares, increasing direct ownership by 44% to 293,177 units (SEC Form 4)
- Director Cheung Ivan converted options into 89,312 shares (SEC Form 4)
- Director Amouyal Philippe converted options into 89,312 shares, increasing direct ownership by 31% to 374,486 units (SEC Form 4)
- Director Barker Sam L converted options into 89,312 shares, increasing direct ownership by 72% to 213,771 units (SEC Form 4)
- Director Debbane Raymond converted options into 89,312 shares, increasing direct ownership by 5% to 1,995,498 units (SEC Form 4)
- Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
- Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
- Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG